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Abstract The complement system is an ancient and evolution-
arily conserved effector system comprising in mammals over
50 circulating and membrane bound proteins. Complement has
long been described as belonging to the innate immune system;
however, a number of recent studies have demonstrated its key
role in the modulation of the adaptive immune response. This
review does not set out to be an exhaustive list of the numerous
interactions of the many complement components with adap-
tive immunity; rather, we will focus more precisely on the role
of some complement molecules in the regulation of antigen
presenting cells, as well as on their direct effect on the activa-
tion of the core adaptive immune cells, B and T lymphocytes.
Recent reports on the local production and activation of com-
plement proteins also suggest a major role in the control of
effector responses. The crucial role of complement in adaptive
immunity is further highlighted by several examples of dysreg-
ulation of these pathways in human diseases.
Keywords Complement . Adaptive immunity . Tcells . B
cells . CD46 . Inflammation
Introduction
For many years, the complement system has been described as
being a key element in innate immunity. This ancient evolu-
tionary system is indeed crucial to fight pathogens, by patrol-
ling as sentinels in the circulation and targeting these invaders
for destruction, as well as initiating inflammatory responses [1].
In the past decade, it has become clear that components of the
complement system also represent an integral part of the regu-
lation of the adaptive immune response. Indeed, complement
components and their receptors are expressed and produced by
adaptive immune cells. The interaction of complement proteins
and their cognate receptors has been shown to control several
functions ranging from activation, differentiation, and metabo-
lism of adaptive immune cells [2]. The recent discovery that
complement is not only present in serum and other fluids but
also has been shown to be activated intracellularly, including in
lymphocytes, opens novel doors on the role of the complex
interactions between this innate system and the control of adap-
tive immune responses [3]. This review will present recent
advances in this field, with a particular focus on the regulation
of B and T cell activation by complement components, and
how dysregulation of these controls can lead to pathogenesis.
Adaptive immunity
Immune responses have traditionally been grouped into either
innate or adaptive responses. The innate response is fast but
non-specific. The complement system is one of the first parts
of the innate response to be activated when Bforeigners^ such as
bacteria invade the body, and it presents an immediate and
critical tool to help defend against infections and clear patho-
gens by allowing their opsonization and further killing [1].
Adaptive immunity on the other hand, although slower, elicits
a very specific immune response through the activation of
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immune cells (T cells and B cells) that express highly specific
antigen receptors. The adaptive immune response is also able to
develop a memory to the antigen, allowing a faster and stronger
response upon re-encounter. In recent years, a finely tuned
interplay between these two types of immune response has
been reported and is now extensively studied. Notably, the
complement system has been shown to directly control B
and T cell responses [2, 4].
Naïve T cells are activated by their cognate TCR following
the recognition of a specific peptide from a given antigen pre-
sented by the MHC, hence conferring the specificity of the T
cell response. Full activation, however, requires co-stimulation
and is provided by the engagement of co-stimulatory molecules
expressed on Tcells and ligated by their cognate receptors at the
surface of antigen presenting cells (APC) [5]. Depending on the
cytokines and signals received by the naïve T cells, these will
differentiate within different T helper (Th) subsets [6]. These
differentiated Th subsets are, however, not static as they exhibit
a certain level of plasticity and are able to modulate their cyto-
kine profiles depending on the surrounding environment and
the signals received. In counterpoint to these effector Th sub-
sets, a variety of regulatory T cells (Tregs) operate, essential to
control immune homeostasis by counteracting overactivation
of effector T cells [7]. Lack of regulatory T cells or dysfunction
of these cells is indeed detrimental to health, giving rise to
allergy or autoimmune diseases.
Similarly, B cells are adaptive immune cells that are specific
to a given antigen. As opposed to T cells, B cells recognize the
whole antigen and not a processed peptide. Recognition of the
antigen is made by the unique B cell receptor (BCR) expressed
at the cell surface, namely a membrane-bound immunoglobulin.
Full activation of B cells also requires co-stimulation alongside
BCR stimulation, such as ligation of the cell surface molecule
CD40. Recent studies have highlighted the existence of specific
regulatory B cells (Bregs) that also contribute to themaintenance
of immune homeostasis in a manner analogous to Tregs [8].
Complement components and their receptors
and regulators modulating adaptive immunity
This review does not expand on the different complement
activation pathways and cascades leading to the formation of
membrane attack complexes (MAC) as this is covered in
depth in other reviews in this issue. We will, however, briefly
describe some of the complement receptors and complement
regulators that are involved in the regulation of the adaptive
immune cells, as further discussed below.
Complement activation results in the generation of C3 and
C5 convertase complexes; these will cleave C3 and C5, re-
spectively, generating the anaphylatoxin components C3a and
C5a as well as the opsonin C3b and MAC initiator C5b.
Binding of C3 and C5 fragments to their cognate receptors/
regulators triggers intracellular signaling resulting in the mod-
ulation of key cellular functions.
Complement receptors
CD21, also called complement receptor 2 (CR2), is a cell
surface glycoprotein which binds and recognizes a variety of
ligands, such as the Epstein-Barr virus, the IgE receptor
CD23, IFNα, and the complement C3 degradation products
C3d, iC3b, and C3d,g. CD21 profoundly modulates B cell
functions, as further discussed below.
Complement C3a receptor, C3aR, is a G-protein-coupled
receptor (GPCR) which interacts with complement compo-
nent C3a. C3aR has been shown to be present on both B cells
and T cells; however, much of the literature has focused on its
role in modulating T cell-mediated immunity [9]. In resting T
cells, C3aR is only expressed intracellularly within lyso-
somes, while upon activation, the receptor is translocated to
the plasma membrane [3].
Complement C5a receptor 1, C5aR1 (CD88), is a GPCR
which binds to the complement components C5a and
desarginated C5a (C5adesArg). Although initially suggested that
C5adesArg bound to C5aR1 with less affinity than C5a [10], this
was recently challenged [11]. Its localization appears to be
somewhat dependent on cell type, as it is detected both in the
cytoplasm and on cell membrane in monocytes whereas it
appears to be exclusively localized within the cell in T cells
[12, 13]. C5aR1 is present on a variety of cell types, not ex-
clusively immune cells. Its interaction with C5a is believed to
be pro-inflammatory and contributes to the pathogenesis of
several inflammatory diseases.
C5aR2 (or C5L2) binds to both C5a and C5adesArg with
comparable affinity to C5aR1. C5aR2 is a seven-transmembrane
domain receptor, localized primarily intracellularly but also
expressed on the cell membrane [12]. C5aR2 shares 38% se-
quence homology with the C5aR1 receptor but does not couple
to G proteins [14]. The lack of GPCR-coupled signaling led to
the belief that this receptor was a Bdecoy^ receptor with no other
function than to compete for C5a binding with C5aR1 [15].
However, recent studies have shown that C5aR2 can recruit
and signal through β-arrestin, having both pro- and anti-
inflammatory effects depending on the cell type and signaling
conditions [13].
Complement regulators
CD46, also known as membrane co-factor protein (MCP), is a
member of the regulators of complement activation (RCA)
family. CD46 is ubiquitously expressed (except for erythro-
cytes) and, along with other complement regulators, protects
cells from autologous complement mediated lysis, by binding
to complement components C3b and C4b and facilitating their
degradation by factor I. CD46 also acts as a receptor for
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several pathogens including measles and adenoviruses and the
Neisseria (N) gonorrhoeae and N meningitides bacteria [16].
In addition, CD46 is a powerful regulator of T cell-mediated
immunity, as further discussed below.
CD55, also known as decay accelerating factor (DAF), is a
glycosylphosphatidylinositol (GPI)-anchored cell surface
molecule, and a member of the RCA family. CD55 promotes
the degradation and inhibits the formation of complement C3
and C5 convertases and thus prevents amplification of the
complement cascade and formation of the MAC.
CD59, another GPI-anchored molecule, prevents
complement-mediated lysis of autologous cells by inhibiting
the interaction between complement C9 and C5b-8 complex,
hence preventing the formation of the MAC [17].
CD35, or complement receptor 1 (CR1), is a transmembrane
glycoprotein and amember of the RCA family. CD35 binds the
ligands C3b, iC3b, and C4b. Like CD55, CD35 has decay
accelerating activity promoting the degradation of complement
C3 and C5 convertases. However, unlike other members of the
RCA family, CD35 possesses both decay accelerating activity
and cofactor activity for factor I-mediated complement cleav-
age. CD35 catalyzes factor I cleavage of iC3b to C3c and
C3dg, the latter being a ligand for CD21 [18].
C4b binding protein (C4BP) is a multimeric serum soluble
glycoprotein produced and secreted primarily by the liver.
Several isoforms of C4BP exist, composed of various combi-
nations of alpha and beta chains. C4BP has both decay accel-
erating activity and cofactor activity for factor I-mediated
cleavage, resulting in the dissociation of C3 convertases and
degradation of C3b and C4b, respectively. Serum localized
C4BP forms a complex with vitamin-K-dependent protein S,
which allows binding to negatively charged phospholipids
such as the apoptotic cell marker phosphatidylserine [19].
The binding of C4BP to apoptotic cells inhibits complement
C3 and C5 convertase formation and subsequent lysis by
MAC formation, preventing the induction of an inflammatory
response due to excessive complement activation and the re-
lease of cellular contents due to cell lysis [20].
Factor H (FH) is a soluble complement regulator present in
the plasma [21]. It binds and inhibits C3b. Factor H acts as a
co-factor for factor I-mediated cleavage of complement com-
ponent C3b to iC3b, preventing the assembly of the C3bBb
alternative pathway C3 convertase. Factor H can also facilitate
the decay of already formed C3bBb C3-convertase by
displacing bound Bb from C3b.
Complement in APC function
One of the primary functions of the innate immune system is
the recognition, uptake, and presentation of foreign pathogens
to activate the adaptive immune system. Upon recognition of
an antigen by APC, such as dendritic cells (DCs), the entity is
engulfed, digested, and the subsequent antigenic peptide is
presented on MHC receptors at the APC surface to activate
the specific T cells. The serum complement system forms an
integral part of this process through the opsonization of foreign
entities, which improves antigen recognition and uptake into
APCs via complement receptors CD21 and CD35 [22]. DCs,
along with macrophages and mast cells, are one of the largest
producers of extra-hepatic C1q which induces cellular re-
sponses on local tissues in a paracrine manner [23]. C1q in-
duces maturation of DCs and upregulates expression of cell
surface MHC class II and CCR7, the latter being a chemokine
receptor necessary for DC migration towards the lymphoid
tissue [24]. C1q-matured DCs also secreted higher amounts
of IL-12p70 which in turn stimulates a greater Th1 response
from co-cultured T cells [24]. However, C1q bound to apopto-
tic cells induced DCs to secrete IL-10 as opposed to IL-12p70,
suppressing Th1 and Th17 cell proliferation [25]. DC produc-
tion of C1q ceases upon maturation, which may represent a
negative feedback loop, limiting DC maturation; it may also
serve to restrict C1q production in lymphoid tissues where it
could have a direct impact on B and T cell responses [23].
In a model of influenza infection, C3 is required for the
migration of lungDCs to the lymph nodes [26]. CD46 ligation
by measles virus or antibodies on human DCs has been re-
ported to modulate secretion of the pro-inflammatory cyto-
kines IL-12 and/or IL-23 [27–29]. Hence, complement mod-
ulates the ability of DCs to migrate towards the lymphoid
tissue and modulates the adaptive response through regulation
of cytokine secretion. Local production of C3a and C5a at the
APC–T cell interface is also key to regulate T cell activation
and survival [30]. Exogenous FH also modulates the matura-
tion and function of DCs and their ability to stimulate T cells.
Treatment of monocyte-derived DC (MoDC) with FH prior to
LPS stimulation resulted in the generation of a phenotypically
immature MoDC population. These cells displayed reduced
antigen uptake, CCR7 expression, and chemotactic ability.
When co-cultured with CD3+ T cells, they induced a
CD4+CD127lowCD25highFoxp3+ regulatory T cell population
[31]. In concordance with these observations, it was shown
that IFNγ-activated DCs resulted in increased expression of
cell surface factor H. Inhibition of factor H expression resulted
in increased CD4+ T cell activation and proliferation. These
findings suggest a role for factor H in the regulation of DC
function and its modulation of T cell responses [32].
Role of complement in B cell regulation
Complement plays a modulatory role in a variety of B cell
functions, including activation and differentiation, antigen in-
ternalization and presentation, and immunoglobulin class
switching. The importance of these interactions is highlighted
by the variety of diseases that can occur when the complement
system becomes dysregulated.
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B cell activation
Naive B cells require two activation signals to become opti-
mally activated, begin proliferating and generating antigen spe-
cific antibodies. The first activation signal is propagated
through the stimulation of the BCR and its co-receptor com-
plex composed of complement receptor 2 (CR2, CD21)/CD19/
CD81 [33]. The second activation signal typically involves
CD40 on B cells and its cognate ligand on T cells, CD154
(CD40L) [34]. Co-engagement of the BCR and of CD21 by
C3d-opsoninized antigen enhances B cell activation [4, 35], by
reducing the amount of antigen required for activation by be-
tween two- and four-fold; thus, C3d has been described as an
antigen adjuvant. Co-engagement of the BCR and CD21/CR2
is also key to the generation of B cell memory [4].
B cell surface complement receptor 1 (CD35, CR1) binds
to the complement components C3b and C4b, acting as a co-
factor to facilitate their cleavage by factor I to iC3b, a substrate
for CD21, and iC4b, respectively [36]. While CD21, as men-
tioned previously, promotes B cell activation, CD35 has an
antagonistic effect, suppressing B cell activation and prolifer-
ation [37].
Antigen internalization and presentation
The interaction of C3 fragments with CD21 plays a fundamen-
tal role in B cell antigen internalization and presentation [38].
Internalized antigen is processed and the peptide presented on
surface MHC-Cl.II receptors to activate local T cell responses
[39]. Brimnes et al. [40] observed that B cells incubated in
either serum-free media or with heat or chemically inactivated
complement showed significantly reduced ability to uptake
antigen. Blockage of CD21 with polyclonal antibodies also
significantly reduced antigen uptake and presentation. The B
cell uptake of complement C3d-coated antigen plays an impor-
tant role in formation and maintenance of germinal centers and
the subsequent differentiation of memory and effector B cells.
B cells are observed to transfer complement-coated antigen to
follicular DCs via the CR2 receptor; these store the antigen,
periodically transferring it back to the B cells to maintain the
germinal centers and extend the humoral response [22, 41].
Immunoglobulin class switching
The complement receptor CD21 and the complement regula-
tors CD46 and C4BP modulate B cell immunoglobulin class
switching, particularly IgE switching. Resting B cells typical-
ly express the IgM or IgD immunoglobulin isotypes. Upon
differentiation, B cells switch their class immunoglobulins
depending on surrounding cytokines and interaction with cell
surface receptors such CD40 and the IgE receptor CD23. The
earliest indication of the involvement of CD21 in IgE class
switching was the discovery of its ability to bind to CD23
[42]. CD21 bound to either soluble CD23, Epstein-Barr virus
fragments or monoclonal antibodies in the presence of the
stimulatory signals IL-4 and anti-CD40, results in an in-
creased production of mature IgE mRNA and secreted IgE
[42, 43]. Geha’s group reported that the complement regulator
C4BP binds to B cell surface CD40 inducing B cell activation
and proliferation, and, in the presence of IL-4, also induces
immunoglobulin class switching to promote the secretion of
IgE [44]. Although CD46 stimulation has been observed to
increase IgE germline transcripts, this does not result in in-
creased secretion of IgE [45]. Moreover, co-ligation of CD46
with CD40 on B cells inhibits IgE class switching through
blockage of CD40-mediated NFκB activation. Hence, a vari-
ety of complement components can differentially modulate
IgE secretion depending on the target receptors involved. A
summary of the roles of complement in antigen presentation
and B cell function is depicted in Fig. 1.
Role of complement in T cell activation
A growing body of evidence suggests that several members of
the complement family interact with CD4+ T cells through
interaction with cell surface and intracellular receptors modu-
lating activation and subset differentiation.
T cell activation and differentiation
Activation by CD46 has been shown to profoundly affect Tcell
activation. Co-stimulation by CD3/CD46 transduces signals
resulting in a strong proliferative response of activated T cells
[46–48], and differentiation into Th1 cells characterized by
IFNγ production [49]. As IL-2 accumulates in the surroundings
of the cells, a contraction phase occurs, with decreased IFNγ
production but enhanced secretion of IL-10. The release of high
levels of IL-10 and low IFNγ leads to suppression of prolifer-
ation of bystander T cells; hence, CD46-costimulated T cells
acquire a phenotype of so-called type I regulatory T cells (Tr1)
[50]. CD46 co-stimulation modulates expression of Notch fam-
ily members at the surface of activated T cells, while on resting
T cells, CD46 binds to the Notch family member Jagged1,
inhibiting both Notch signaling and CD46 activation.
Activation of CD46 leads to CD46 downregulation, freeing
Jagged 1 to interact with Notch [51]. Interestingly, Notch reg-
ulates IL-10 secretion in Th1 cells [52]. Hence, CD46 may
provide the link between the Notch and complement cascades
to regulate T cell differentiation and IL-10 production.
Enzymatic processing of CD46 occurs upon T cell activa-
tion, leading to the shedding of its extracellular domain and
subsequent cleavage of its two cytoplasmic tails, Cyt1 and
Cyt2. The two tails exhibit antagonistic roles in the control
of inflammation, in both huCD46-transgenic mice (mice only
express CD46 on testis) [53] and in human Tcells in vitro [54,
55]. Processing of CD46 is required for IL-10 production and
Semin Immunopathol
allows T cell activation but also T cell termination [54, 55].
Both tails contain a nuclear localization signal (NLS) se-
quence, and indeed, cleaved tails translocate to the nucleus
likely controlling target genes [56]. CD46 expression on acti-
vated T cells is tightly controlled [57–60]. Vitamin D, for
example, which is known to promote immune regulation,
Fig. 1 Complement regulation of dendritic and B cell functions. The
interaction of complement component C1q with dendritic C1qR results
in differential responses dependent on its ligand. C1q bound to microbial
surfaces results in DC maturation, increased expression of MHC-II and
CCR7, and increased secretion of IL-12p70 resulting in improved ability
to present antigen, migration towards the lymphoid tissue and promotion
of Th1 effector cell differentiation, respectively. However, C1q bound to
apoptotic cells results in secretion of the anti-inflammatory cytokine IL-
10 as opposed to IL-12p70 resulting in activation of regulatory T cells.
C3b and C3d complement coated antigen is bound by antigen presenting
cell surface CD21 and CD35 complement receptors, assisting in antigen
uptake. The internalized antigen is degraded to antigenic peptide and
presented on the surface MHC-II. B cell activation is regulated by
complement C3d or C3b binding to cell surface CD21 or CD35
resulting in either a reduction in activation threshold or an inhibition of
activation, respectively. Complement component C4BP interacts with a
variety of ligands including complement C3b and B cell surface CD40.
Interaction of C4BP with CD40 alone induces B cell activation,
proliferation, and antibody class switching from IgM to IgE. However,
C3b bound C4BP can bridge interactions between CD46 and CD40
which results in inhibition of CD40 mediated antibody class switching
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triggers the Th1 to Tr1 switch and favors CD46 cleavage [60].
Expression of CD46 on activated T cells is also under control
of a crosstalk with CD28 [61]. Regulation of the splicing of
the Cyt1 exon have been recently reported [62]. A few
interactors of CD46 tails (albeit only with Cyt1) have been
identified, leading to the discovery of the role of CD46 in
controlling autophagy (via interaction with GOPC) [63] and
cell polarity via binding to DLG4 [64, 65]. Cyt1 interacts with
the kinase SPAK, and this is required for IL-10 production
[49]. CD46 also interacts with alpha-E-catenin in human
CD4+ T cells and knockdown of α-E-catenin impaired
CD46 downregulation suggesting a role for α-E-catenin in
CD46-controlled expression [51]. CD46 is recruited to lipid
rafts [66] and T cell polarization is affected by CD46 ligation
[47, 65]. CD46 ligation before specific T cell activation can
prevent subsequent TCR signaling by recruiting the lipid rafts
and preventing the immune synapse formation [65], while co-
ligation with the TCR promotes its recruitment to the immune
synapse (S. Ni Choileain, J. Hay, et al., submitted). Together,
these studies highlight the key role of CD46 signaling on
controlling T cell differentiation and function.
Other members of the RCA family also control T cell acti-
vation. Similar to CD46, CD55 affects co-stimulation of hu-
man T cells by binding to CD97, promoting T cell activation
and Tr1 cell differentiation [67]. In mice, it was observed that
the lack of CD55 promotes T cell activation, suggesting an
inhibitory role of CD55 in T cell effector function [68, 69]. A
role for CD59 in T cell co-stimulation has also been reported
[70] and shown to couple signaling events to the TCR [71].
Moreover, recent studies have highlighted an immunomodu-
latory role of CD59 in T cells suggesting that its ligation may
also potentially induce a regulatory T cell subset [72].
Not only complement regulators but also complement re-
ceptors modulate T cell function and survival. In mice, C5aR
and C3aR act as costimulatory signals for T cells and sustain
naive T cell survival [30]. C3aR is not expressed at the cell
surface of naïve T cells but on lysosomes and is transported to
the surface upon T cell activation [73]. Defective cytokine
secretion by T cells from C3ar1−/− and C5ar1−/− mice show
that these receptors are also needed for effector function [30].
In addition, these complement receptors control Treg function.
nTregs express C3aR and C5aR, and triggering of these re-
ceptors inhibits Treg suppressive function by modulating
Foxp3 expression [74]. C3aR−/− and C5aR−/− mice have in-
creased levels of Foxp3 + Tregs [75]. Similarly, blocking these
receptors with C3aR and C5aR antagonists in human T cells
induced suppressive human iTregs [75].
Production of local and intracellular C3 and C5 in T cells
Until recently, it was thought that soluble complement com-
ponents were mostly present in the plasma after production
mainly by the liver. In recent years, a series of papers have
demonstrated the local production of C3 and C5 fragments by
adaptive immune cells. In mice, Tcell-derived C3 activation is
due to the formation of C3 convertase [30]. In contrast, in
resting human T cells, a recent report suggests that there is
continuous production of C3 that is cleaved by cathepsin L
(CTSL), giving rise to C3a and C3b [3]. The resulting C3a
binds to its C3aR at the surface of lysosomes and participates
to T cell survival by regulation of mechanistic target of
rapamycin (mTOR) activity [3]. Upon TCR activation, both
C3a and C3b are exported to the cell surface within minutes
and bind to surface C3aR, also expressed at the surface after
activation, and CD46, respectively, leading to Tcell activation
and Th1 differentiation. Uncontrolled cleavage results in hy-
peractivation of Th1 responses, such as that observed in a
small number of patients with rheumatoid arthritis, and in-
deed, inhibition of CTSL normalized the response [3].
Interestingly, CTSL has been linked to inflammatory re-
sponses and IL-17 production by controlling Th17 differenti-
ation in both humans and mice [76, 77], suggesting a broader
role of cathepsins in regulating inflammatory conditions. This
also suggests a role of the C3 and C5 fragments in modulating
Th17 response.
The same group recently reported the intracellular cleavage
of C5 in T cells upon co-stimulation by CD3/CD46 [12].
Binding of cleaved C5a to intracellular C5R1 leads to activation
of the NLRP3 inflammasome in T cells, and IL-1β production
has been reported [12]. The NLRP3-IL-1β axis participates in
the activation of CD46 in T cells and IFNγ production. On the
other hand, binding of C5a to C5aR2 that is expressed at the cell
surface inhibits this pathway [12]. Of note, we have failed to
detect any IL-1β secreted upon CD46 costimulation of T cells
from either healthy donors or patients with multiple sclerosis
(A. Itchers, J. Killick, A. Astier, unpublished data), and the
reasons for these discrepancies are unknown and may relate
to the sensitivity of the assays used. Further research will allow
clarification on the role of this pathway in T cell differentiation.
It is important to note that key differences between men
and mice have been reported. Local production of C3 and
C5 fragments has been demonstrated in mice, although this
was thought to be due to increased C3 expression and ex-
tracellular cleavage by the C3 convertase [78]. Moreover,
although CTSL and C3 are present in murine T cells, nor-
mal Th1 differentiation occurred in T cells from CTSL
knockout mice, suggesting that C3 fragments do not re-
quire CTSL processing in murine T cells, as opposed to
human cells [3]. Moreover, mice do not express CD46
(except for testis), implying that the interaction between
C3b and CD46 is not required to generate a Th1 response.
It would be interesting to assess the role of the C3b recep-
tor and complement regulator Crry in this response, espe-
cially as Crry has been also shown to act as a costimulatory
molecule for murine T cells [79], similarly to CD46 en-
gagement on human T cells [46].
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Importantly, although the role of intracellular complement
activation has so far been only shown in human CD4 T cells,
intracellular complement activation has been observed in sev-
eral cell types by the authors, suggesting that this is a general
biologic process necessary to overall cell function [3], and the
term Bcomplosome^ has recently been suggested [80].
Role of complement in T cell metabolism
Resting T cells typically have low energy requirements needed
to maintain homeostatic functioning. As such, they require
only a limited influx of nutrients and have low glycolytic ac-
tivity, instead deriving energy through mitochondrial oxidative
phosphorylation. Upon activation, the energy requirements of
the cells rise to support the increased energy demands of cel-
lular proliferation and effector functions [81, 82]. To meet this
demand, the activated cells enhance generation of ATP through
both glycolysis and oxidative phosphorylation pathways. This
process of metabolic adaption to meet the increased energy
demands is referred to as metabolic reprogramming. Upon
activation, T cells upregulate surface expression of the glucose
channel GLUT1 [83] and the amino acid channel LAT1 [84]
resulting in increased influx of nutrients. This increased nutri-
ent uptake, particularly the augmented influx of amino acids
through the LAT1 channel, is sensed by mTOR [85, 86]. This
subsequently enhances the expression of the transcription fac-
tors myc and HIF1α, resulting in increased expression of the
glycolytic machinery required for metabolic reprogramming
and effector function [85, 87]. While a limitation of glucose
availability severely impacts T cell activation and effector
function [84, 87, 88], T cells display improved effector func-
tion with increased glucose [88].
As discussed earlier, upon TCR activation intracellular
stores of C3a and C3b are translocated to the cell surface
where they interact with cell surface C3aR and CD46, respec-
tively [30, 49]. The interaction between C3b and CD46 mod-
ulates the metabolic reprogramming dependent on the CD46
cytoplasmic tails [56]. CD46–Cyt1 isoform when bound by
C3b signal an increase in cell surface expression of the glu-
cose channel, GLUT1 and the amino acid channel, LAT1, by
modulation of miR-150 expression [89]. Moreover, an in-
crease in the expression of MAPK and the mTOR activator
5 (LAMTOR5), which resulted in increased mTOR assembly
and glycolysis, was observed. In contrast, activation of the
CD46–Cyt2 isoform resulted in a decrease in the rate of gly-
colysis towards levels observed prior to activation, resulting in
Th1 contraction and increased secretion of IL-10. Hence,
CD46, depending on its cytoplasmic domain, may lead to
increased metabolic state supporting proliferation and effector
function of activated T cells before mediating a switch to a
lower glycolytic profile encouraging Th1 contraction and gen-
eration of suppressive IL-10 secreting T cells. The key role of
CD46 in T cell activation is summarized in Fig. 2. Of note,
enzymatic processing of the tails is required to control T cell
activation and cytokine production. While cleavage of Cyt1 is
required to promote IL-10 production, cleavage of Cyt2 was
shown to decrease IFNγ production and reduce overall T cell
function [54, 55]. Hence, it is clear that the balanced expres-
sion of the tails profoundly governs T cell function, and a
deeper understanding of the mechanisms regulating their ex-
pression and function is needed.
Aberrant complement regulation in human diseases
The importance of complement in controlling immune ho-
meostasis is highlighted by the dysregulation of these path-
ways in a large number of diseases. Analysis of the circulating
complement products may also act as biomarkers, as for ex-
ample increased levels of complement components offer a
differential diagnosis between MS and the relatively close
neuromyelitis optica spectrum disorder [90]. As discussed
earlier, CD46 is key in regulating T cell function. The CD46
pathway has been shown to be dysfunctional in a number of
chronic inflammatory diseases. An impaired production of IL-
10 upon CD46 co-stimulation was observed in patients with
relapsing-remitting multiple sclerosis (MS). This was specific
to CD46 costimulation as levels of IL-10 were normal when T
cells were activated by CD28, indicating a specific defect in
the CD46 pathway [57, 91, 92]. As mice do not express CD46
on somatic cells, the role of CD46 has been studied using an
MSmodel inmonkeys that express CD46 on every cell type in
a similar fashion to man (although unlike humans, non-human
primates also express CD46 on red blood cells), and a similar
dysfunction of the regulatory function of CD46 on Tcells was
observed [93]. The lack of regulatory Th1-Tr1 switch was also
reported in rheumatoid arthritis [49] as well as asthma patients
[94, 95]. Hence, chronic inflammation switches CD46 to-
wards an inflammatory response. This was also observed for
DCs in MS as CD46-activated DCs produce increased levels
of pro-inflammatory IL-23 and chemokines compared to
healthy DCs [29]. The exact molecular mechanisms responsi-
ble for this inflammatory switch during inflammation are not
totally understood and warrant further research. T cell activa-
tion leads to a change in glycosylation of CD46 that is required
for correct signaling and processing. This regulatory mecha-
nism appears to be altered in T cells from patients with MS,
leading to a dysfunctional pathway (S. Ni Choileain, J. Hay,
et al., submitted). Importantly, the key role of CD46 in con-
trolling T cell differentiation is supported by the analysis of
CD46-deficient patients. These patients exhibit reduced Th1
cell-mediated responses along with recurrent infections [51].
Similarly, studies using Tcells fromC3-deficient patients have
highlighted the importance of C3 in Th1 responses. These
patients exhibit impaired secretion of IFNγ and IL-10.
Blockage of C3aR in healthy CD4+ T cells also resulted in
diminished IFNγ secretion and IL-10 switching [73]. In both
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CD46- and C3-deficient patients, Th2 responses appeared to
remain intact [51].
As mentioned previously, CD35 suppresses B cell activa-
tion [37]. Reduced expression of CD35 in a number of auto-
immune conditions such as rheumatoid arthritis and systemic
lupus erythematosus (SLE) has been obsvered, although
whether these reduced levels contribute to disease remains to
be firmly established [96].
Due to the high occurrence of the autoimmune condition
SLE associated with C1q deficiency [97], C1q is believed to
play a role in immune tolerance [98]. C1q binds directly to the
apoptotic cell marker phosphatidylserine which aids in the
clearance of apoptotic cells by the innate immune system
[99]. C1q deficiency leads to accumulation of apoptotic cells
and Bblebs^ containing large quantities of nuclear antigen such
as dsDNAwhich may lead to an auto-immune response [98].
Targeting CD46 as therapy
The analysis of the in vivo function of CD46 has been largely
impaired by the lack of expression of CD46 on somatic cells in
mice. Non-human primates are the only animals expressing
CD46 in a similar fashion as humans. There have been a few
models of CD46-transgenic mice established, and we are de-
veloping a model of CD46-expressing zebrafish that will allow
the tracking of CD46-expressing Tcells upon inflammation and
Fig. 2 T cell activation induces autocrine and intracellular complement
activation that regulates T cell metabolic function and inflammasome
formation. T cell activation by TCR/CD28 results in the intracellular
generation of C5a and the cathepsin L-mediated cleavage of
intracellular C3 to C3a and C3b. Intracellular C5a activates cytosolic
C5aR1, in addition to being translocated to the plasma membrane
allowing interaction with the cell surface C5aR2. Activation of C5aR1
leads to an increase in intracellular ROS generation, which in turn results
in the formation of the NLRP3 inflammasome complex. Activation of
C5aR2 by cell secreted C5a negatively regulates this process. Lysosomes
containing the C3 cleavage products C3a and C3b are shuttled to the cell
membrane leading to C3a andC3bmediated autocrine activation of C3aR
and CD46, respectively. Activation of cell surface C3aR results in
decreased expression of the regulatory T cell transcription factor
FOXP3 and increased Th1 effector functions and IFNγ secretion. Cell
surface CD46 forms a complex the Notch signaling activator Jagged1.
Upon interaction of C3b to CD46, CD46 extracellular region is cleaved
by metalloproteases and its intracellular cytoplasmic domains further
cleaved by a presenilin-gamma secretase complex. Cleavage releases
Jagged1 resulting in activation of the Notch signaling pathway.
Translocation of the CD46 cytoplasmic tail to the nucleus results in in-
creased expression of GLUT1 and LAT1 nutrient transporters,
mTOR, and the NLRP3 inflammasome
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provide a potential model to screen drugs affecting this pathway
(G. Morisse, D. Sieger, A. Astier, unpublished data). Targeting
of the complement regulatory function of CD46 with mutant
proteins derived from adenovirus Ad35 that bind to CD46 with
very high affinity enhances response to Rituximab, an anti-
CD20 antibody in lymphomas in non-human primates [100].
Moreover, this mutant protein was also able to modulate
the CD46 pathway in T cells, suggesting that it may be
used to modulate other diseases, independently of its com-
plement regulatory function [101]. These data underline
that targeting of complement pathways may be a valid ap-
proach for future therapies.
Conclusion and perspectives
Complement components and their interactions with their
cognate receptors are therefore key in the control of adaptive
immune responses. The most studied cells so far have been T
cells, and as discussed above, complement regulates T cell
activation, differentiation, and metabolism. This offers the
perspective of using complement components as novel drug
targets for chronic inflammatory diseases and autoimmune
diseases. Intracellular activation of complement is now sug-
gested not only in immune cells but also in other cells.
Intriguingly, this suggests a much broader role of complement
in general cell functions. There is no doubt that research in the
coming years will reveal unexpected roles for complement in
this regard and highlight how this ancient evolutionary system
plays a much more preponderant role in the control of basic
cellular mechanisms than initially thought.
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